{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T19:37:56Z","timestamp":1772825876307,"version":"3.50.1"},"reference-count":81,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2014,8,18]],"date-time":"2014-08-18T00:00:00Z","timestamp":1408320000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2015,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Targeted therapies represent a major breakthrough in the treatment of adult acute lymphoblastic leukaemia (<jats:styled-content style=\"fixed-case\">ALL<\/jats:styled-content>). Because lymphoblastic leukaemia cells express a variety of specific antigens, those ones can serve as targets for monoclonal antibodies (MoAbs). Anti\u2010<jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>20 (rituximab), anti\u2010<jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>19 (blinatumomab, <jats:styled-content style=\"fixed-case\">SAR<\/jats:styled-content>3419), anti\u2010<jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>22 (epratuzumab, inotuzumab ozogamicin) and anti\u2010<jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>52 (alemtuzumab) have therefore been developed. Possible strategies even include recruitment of <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>3 cytotoxic T cells (blinatumomab) or adoptive T\u2010cell therapy by gene transfer of <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>19\u2010chimeric antigen receptors (<jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>19\u2010<jats:styled-content style=\"fixed-case\">CAR<\/jats:styled-content>s). Recent data show that antibody\u2010based therapy is a highly promising treatment approach. However, optimal treatment approach still needs to be defined.<\/jats:p>","DOI":"10.1111\/ejh.12408","type":"journal-article","created":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T09:16:30Z","timestamp":1404206190000},"page":"99-108","source":"Crossref","is-referenced-by-count":27,"title":["Antibody\u2010based therapies in B\u2010cell lineage acute lymphoblastic leukaemia"],"prefix":"10.1111","volume":"94","author":[{"given":"Caroline","family":"Le Jeune","sequence":"first","affiliation":[{"name":"Hematology Department Hospices Civils de Lyon Lyon\u2010Sud Hospital Pierre B\u00e9nite France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Thomas","sequence":"additional","affiliation":[{"name":"Hematology Department Hospices Civils de Lyon Lyon\u2010Sud Hospital Pierre B\u00e9nite France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,8,18]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24862"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12239"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-547695"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.1382"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2010.07.007"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.268"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07185.x"},{"key":"e_1_2_8_9_1","first-page":"1783","article-title":"Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL)","volume":"9","author":"Bene MC","year":"1995","journal-title":"Leukemia"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2010.529206"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.559668"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-003-0752-8"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001622-199811000-00012"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.41.6768"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2011.1.243"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M708459200"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-151860"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.010306"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-06-164129"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.30156"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016"},{"key":"e_1_2_8_23_1","first-page":"1","article-title":"Role of rituximab in first\u2010line treatment of chronic lymphocytic leukemia","volume":"7","author":"Bryan J","year":"2010","journal-title":"Ther Clin Risk Manag"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1976.tb03563.x"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055759"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20143"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05141.x"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21776"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2009.07.005"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.2.495.bloodjournal872495"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2011.08.001"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.9456"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06465.x"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-186999"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190902934944"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.037390"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190902878471"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1254"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08315.x"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2013.02.011"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon.13.219"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-225979"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-404368"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.240"},{"key":"e_1_2_8_45_1","first-page":"996","article-title":"Bexxar, iodine I131 tositumomab, effective in long\u2010term follow\u2010up of non\u2010Hodgkin's lymphoma","volume":"6","author":"Kaminski M","year":"2007","journal-title":"Cancer Biol Ther"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.076"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1158545"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00063"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.7270"},{"key":"e_1_2_8_50_1","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.1200\/jco.2012.30.15_suppl.6500","article-title":"Effect of anti\u2010CD19 BiTE blinatumomab on complete remission rate and overall survival in adult patients with relapsed\/refractory B\u2010precursor ALL","volume":"30","author":"Topp M","year":"2012","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.100073"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0485"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3613"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2011.09.015"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0674"},{"key":"e_1_2_8_56_1","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/asheducation.V2012.1.143.3798224","article-title":"Novel cellular therapies for leukemia: CAR\u2010modified T cells targeted to the CD19 antigen","author":"Brentjens RJ","year":"2012","journal-title":"Hematol Educ Program Am Soc Hematol"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215134"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-371971"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1475"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2007.05.018"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210370"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.3528"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12778"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.7863"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12183"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.2174\/1381612003398564"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.3240341"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70386-2"},{"key":"e_1_2_8_69_1","doi-asserted-by":"crossref","first-page":"7092","DOI":"10.1200\/jco.2013.31.15_suppl.7092","article-title":"Phase I\/II study of the combination of inotuzumab ozogamicin (CMC\u2010544) with low\u2010intensity chemotherapy in patients (pts) with acute lymphoblastic leukemia (ALL)","volume":"31","author":"Jain N","year":"2013","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-1374"},{"key":"e_1_2_8_71_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2980"},{"key":"e_1_2_8_72_1","doi-asserted-by":"crossref","first-page":"345a","DOI":"10.1182\/blood.V114.22.839.839","article-title":"Phase I clinical trial of the anti\u2010CD22 immunotoxin CAT\u20108015 (HA22) for pediatric acute lymphoblastic leukemia","volume":"114","author":"Wayne AS","year":"2009","journal-title":"Blood"},{"key":"e_1_2_8_73_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.679267"},{"key":"e_1_2_8_74_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e3181bdf211"},{"key":"e_1_2_8_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08762.x"},{"key":"e_1_2_8_76_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3554"},{"key":"e_1_2_8_77_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21901"},{"key":"e_1_2_8_78_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22209"},{"key":"e_1_2_8_79_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12154"},{"key":"e_1_2_8_80_1","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1182\/blood.V114.22.838.838","article-title":"Alemtuzumab can be incorporated into front\u2010line therapy of adult acute lymphoblastic leukemia (ALL): final phase I results of a Cancer and Leukemia Group B Study (CALGB 10102)","volume":"114","author":"Stock W","year":"2009","journal-title":"Blood"},{"key":"e_1_2_8_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.10.041"},{"key":"e_1_2_8_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.07.021"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.12408","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.12408","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T05:51:28Z","timestamp":1696225888000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.12408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,18]]},"references-count":81,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["10.1111\/ejh.12408"],"URL":"https:\/\/doi.org\/10.1111\/ejh.12408","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,18]]}}}